Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Coppetelli

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Blood Cancer Journal|July 26, 2012
Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric studyA Andriani, M T Petrucci, T Caravita, et al.
Annals of Hematology|February 2, 2021
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio groupFederico Vozella, A Siniscalchi, M Rizzo, et al.
Blood Cancer Journal|November 26, 2013
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II studyM Offidani, L Corvatta, L Maracci, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Blood Cancer Journal|July 26, 2012
Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric studyA Andriani, M T Petrucci, T Caravita, et al.
Annals of Hematology|February 2, 2021
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio groupFederico Vozella, A Siniscalchi, M Rizzo, et al.
Blood Cancer Journal|November 26, 2013
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II studyM Offidani, L Corvatta, L Maracci, et al.
Pageof 2